GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Health Sciences Group HESG · USD

Consumer Staples · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 4 Nov 2026, in USD

About Health Sciences Group

Its shares trade under the ticker HESG. It has been listed since 3 August 2001. In the fiscal year to 31 December 2012, it reported revenue of $358,434 and a net loss of $54,487. At that date it held total assets of $1.0m and shareholders' equity of $595,868.

Health Sciences Group, Inc. is an investment technology portfolio company. The company is headquartered in Indian Harbour Beach, California. The company went IPO on 2001-08-03. The firm has two operating subsidiaries: BioSelect Innovations, Inc. and Swiss Research, Inc. BioSelect Innovations has developed a number of product formulations. These patents address the integration of selective traditional over-the-counter generic drugs with complementary alternative medications, such as vitamins, herbs and other natural nutraceutical supplements. Swiss Research is a diet and nutrition products company, which markets and sells Shugr, a zero-calorie and diabetic safe sugar substitute with the look, taste and baking qualities of cane sugar. The firm will launch its new product, Sequesterol Advance Cardio Formula in April 2006.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Consumer Staples
Industry
Consumer Staples Distribution & Retail
Listed since
3 Aug 2001

Leadership

Pay as last reported

  • Duke BestController
  • Sid AndersonDirector
  • Anthony DeBellaDirector
  • William WalkerDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • BioSelect Innovations develops patented drug formulations integrating generic and natural supplements.
  • Swiss Research markets Shugr, a diabetic-safe sugar substitute with cane sugar properties.
  • Sequesterol Advance Cardio Formula is set for April 2006 launch as a new product.

Weaknesses

  • Headquartered in Indian Harbour Beach, Florida, a small city with limited market access.
  • Operating subsidiaries lack detailed market share data in the facts provided.
  • No mention of financial performance metrics or revenue figures in the business description.

Opportunities

  • Expanding into the growing health and wellness market with new product launches.
  • Leveraging BioSelect's patented formulations for broader retail distribution.
  • Capitalizing on Swiss Research's Shugr product in the diabetic-friendly food segment.

Threats

  • Competition from established players in the retail and health supplement sectors.
  • Regulatory challenges in the US market for new health product formulations.
  • Market saturation in the sugar substitute industry with existing alternatives.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.